Who are Vfend - voriconazole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): medium itraconazole tablet, anidulafungin and voriconazole, Voriconazole clinical practice, Ketoconazole 2% Shampoo, clotrimazole vaginal tablets, Bifonazole Cream.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vfend-voriconazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Vfend - voriconazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vfend - voriconazole (Vfend - voriconazole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Azole antifungal. Area: Infectious Diseases.

phase 3 Azole antifungal Lanosterol 14α-demethylase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Vfend - voriconazole (Vfend - voriconazole) — Pfizer. Voriconazole is an antifungal medication that works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vfend - voriconazole TARGET	Vfend - voriconazole	Pfizer	phase 3	Azole antifungal	Lanosterol 14α-demethylase
medium itraconazole tablet	medium itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal CYP51 (lanosterol 14α-demethylase)
anidulafungin and voriconazole	anidulafungin and voriconazole	Pfizer	marketed	Echinocandin and triazole antifungal combination	β-1,3-glucan synthase (anidulafungin); fungal CYP51/lanosterol 14α-demethylase (voriconazole)
Voriconazole clinical practice	Voriconazole clinical practice	Instituto de Investigación Hospital Universitario La Paz	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
Ketoconazole 2% Shampoo	Ketoconazole 2% Shampoo	Fakultas Kedokteran Universitas Indonesia	marketed	Imidazole antifungal	Fungal cytochrome P450 (CYP51 / lanosterol 14α-demethylase)
clotrimazole vaginal tablets	clotrimazole vaginal tablets	Peking University Shenzhen Hospital	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Bifonazole Cream	Bifonazole Cream	Galderma R&D	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Azole antifungal class)

Pfizer · 3 drugs in this class
Elion Therapeutics, Inc. · 1 drug in this class
Hadassah Medical Organization · 1 drug in this class
Hatem AbuHashim · 1 drug in this class
Janssen Pharmaceutical K.K. · 1 drug in this class
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · 1 drug in this class
Military Hospital of Tunis · 1 drug in this class
Mycovia Pharmaceuticals Inc. · 1 drug in this class
Nuvation Bio Inc. · 1 drug in this class
Purdue Pharma LP · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vfend - voriconazole — Competitive Intelligence Brief. https://druglandscape.com/ci/vfend-voriconazole. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing